Commentary

Provider education, practice champions can ensure successful integration of biosimilars into oncology care

January 6, 2020
By Kashyap Patel, MD Hundreds of millions of people worldwide rely on biologics to manage debilitating conditions and treat serious illnesses.

European Commission approves subcutaneous infliximab biosimilar for RA

November 26, 2019
The European Commission has approved the subcutaneous formulation of Celltrion’s infliximab biosimilar for adult patients with active…
In the Journals

Written, verbal patient education prior to biosimilar switching recommended for JIA

October 28, 2019
Rheumatology practices should provide written and verbal patient education, and supply adequate teaching for all staff, prior to nonmedical…

Celltrion obtains positive CHMP opinion for subcutaneous infliximab biosimilar

September 24, 2019
Celltrion received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for the subcutaneous…
In the Journals

Adalimumab, IBI303 biosimilar demonstrate comparable safety, efficacy in AS

September 19, 2019
IBI303, a biosimilar to adalimumab developed by Chinese biopharmaceutical company Innovent Biologics, is comparable in safety and efficacy to the…
In the JournalsPerspective

ACR cautions against mandated biosimilar switching for AS, axSpA

August 22, 2019
Adults with active ankylosing spondylitis despite treatment with a first TNF-inhibitor, as well as those with stable disease receiving an originator…
FDA News

FDA approves Hadlima, fourth Humira biosimilar

July 24, 2019
The FDA has approved the fourth biosimilar to adalimumab, adalimumab-bwwd, for all eligible indications of the biologic product, according to a…
In the JournalsPerspective

Positive framing improves patients’ willingness to switch to biosimilar

July 11, 2019
Although patients express concerns regarding the safety and efficacy of biosimilars, physicians can improve willingness to switch to a biosimilar by…
FDA News

FDA approves Zirabev, biosimilar to Avastin

June 28, 2019
The FDA approved bevacizumab-bvzr for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic…
FDA News

FDA approves Kanjinti, biosimilar to Herceptin

June 13, 2019
The FDA approved trastuzumab-anns for the treatment of HER2-overexpressing breast cancer, as well as metastatic gastric or gastroesophageal junction…